Dihydropyrimidine dehydrogenase level and the redox status in patients with colorectal cancer are prognostic for adverse effects of fluoropyrimidines

References

• Brown KGM, Solomon MJ, Mahon K, et al. Management of colorectal cancer. BMJ. 2019;366:l4561.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No 11. 2013.
   Google Scholar
• Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691.
   PubMed Web of Science ®Google Scholar
• Loomans-Kropp HA, Umar A. Increasing incidence of colorectal cancer in young adults. J Cancer Epidemiol. 2019;2019:9841295.
   PubMed Web of Science ®Google Scholar
• Labianca R, Nordlinger B, Beretta G, Mosconi D, Mandalà S, Cervantes MA, et al. Early Colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up on behalf of the. Ann Oncol. 2013;24(Supplement 6):vi64–vi72.
   PubMed Web of Science ®Google Scholar
• Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16(12):713–732.
   PubMed Web of Science ®Google Scholar
• Toma M, Beluşică L, Stavarachi M, et al. Rating the environmental and genetic risk factors for colorectal cancer. J Med Life. 2012;5(Spec Issue):152–159.
   PubMedGoogle Scholar
• Pita-Fernández S, González-Sáez L, López-Calviño B, et al. Effect of diagnostic delay on survival in patients with colorectal cancer: a retrospective cohort study. BMC Cancer. 2016;16(1):664.
   PubMed Web of Science ®Google Scholar
• Monjur A. Colon cancer: a clinician’s perspective in 2019. Gastroenterol Res. 2020;13(1):1–10.
   PubMed Web of Science ®Google Scholar
• Chabner BA. General principles of cancer chemotherapy. In: Brunton L, Chabner B, Knollmman B, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. Chapter 60. New York (NY): McGraw Hill Medical; 2011. p. 1667–1675.
   Google Scholar
• Park SH, Sung JY, Han S-H, et al. Oxaliplatin, folinic acid and 5-Fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience. Jpn J Clin Oncol. 2005;35(9):531–535.
   PubMed Web of Science ®Google Scholar
• Pardini B, Kumar R, Naccarati A, et al. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. Br J Clin Pharmacol. 2011;72(1):162–163.
   PubMed Web of Science ®Google Scholar
• Thirion P, Michiels S, Pignon JP, et al. Meta-analysis group in cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004; 22(18):3766–3775.
   PubMed Web of Science ®Google Scholar
• Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011;18(1):18–25.
   PubMed Web of Science ®Google Scholar
• Fischel JL, Formento P, Ciccolini J, et al. Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br J Cancer. 2002;86(7):1162–1168.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Beumer JH, Chu E. Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol. 2016;78(3):447–464.
   PubMed Web of Science ®Google Scholar
• Macaire P, Morawska K, Vincent J, et al. Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years. Eur J Cancer. 2019;111:116–125.
   PubMed Web of Science ®Google Scholar
• Koçer M, Nazıroğlu M. Effects of 5-fluorouracil on oxidative stress and calcium levels in the blood of patients with newly diagnosed colorectal cancer. Biol Trace Elem Res. 2013;155(3):327–332.
   PubMed Web of Science ®Google Scholar
• Chen W, Lian W, Yuan Y, et al. The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress. Cell Death Dis. 2019;10(8):600.
   PubMed Web of Science ®Google Scholar
• Landi M. Commentary to: “Improving the thiobarbituric acid-reactive-substances assay for estimating lipid peroxidation in plant tissues containing anthocyanin and other interfering compounds” by Hodges et al., Planta (1999) 207:604-611. Planta. 2017;245(6):1067.
   PubMed Web of Science ®Google Scholar
• 21. Van Dyke K, Van Dyke C, Woodfork K, editors. Luminescence biotechnology: instruments and applications. Boca Raton (FL): CRC Press; 2002.
   Google Scholar
• Roda A, Guardigli M, Pasini P, et al. Bioluminescence and chemiluminescence in drug screening. Anal Bioanal Chem. 2003;377(5):826–833.
   PubMed Web of Science ®Google Scholar
• Campbell AK. Chemiluminescence: principles and applications in biology and medicine. Cambridge (UK): VCH; 1988.
   Google Scholar
• Minchev V, Hristova-Avakumova N, Kamenova K, et al. Does Dihydropyrimidine dehydrogenase level modifies plasma antioxidant capacity in colorectal cancer patients, treated with fluoropyrimidines? Plovdiv: Flia Medica, University of Medicine. 2021.
   Google Scholar
• Tuomisto AE, Mäkinen MJ, Väyrynen JP. Systemic inflammation in colorectal cancer: underlying factors, effects, and prognostic significance. World J Gastroenterol. 2019;25(31):4383–4404.
   PubMed Web of Science ®Google Scholar
• Kim SE, Paik HY, Yoon H, et al. Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol. 2015;21(17):5167–5175.
   PubMed Web of Science ®Google Scholar
• Schmuck R, Gerken M, Teegen EM, et al. Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients. Langenbecks Arch Surg. 2020;405(1):71–80.
   PubMed Web of Science ®Google Scholar
• Joachim C, Macni J, Drame M, et al. Overall survival of colorectal cancer by stage at diagnosis: data from the Martinique cancer registry. Medicine. 2019;98(35):e16941.
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6(12):4705–4712.
   PubMed Web of Science ®Google Scholar
• Amstutz U, Froehlich TK, Largiadèr CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics. 2011;12(9):1321–1336.
   PubMed Web of Science ®Google Scholar
• Lampropoulou DI. Fluoropyrimidine-induced toxicity andDPD deficiency. A case report of early onset, lethal capecitabine-induced toxicityand mini review of the literature. Uridine triacetate: efficacy and safety as anantidote. Is it accessible outside USA?J Oncol Pharm Practice. 2019;26(3):747–75.
   PubMed Web of Science ®Google Scholar
• Liu H, Liu X, Zhang C, et al. Redox imbalance in the development of colorectal cancer. J Cancer. 2017;8(9):1586–1597.
   PubMed Web of Science ®Google Scholar
• Robev B, Hristova-Avakumova N, Nikolov R, et al. Impact of combination chemotherapy on plasma antioxidant status in lung cancer patients. C R Acad Bulg Sci. 2021;74(2):292–299.
   Google Scholar
• Mahmood NA. Oxidative stress and antioxidant status in colorectal cancer and healthy subject. Iraqi J Cancer Med Genetics. 2010;3(1):1–6.
   Google Scholar
• Skrzydlewska E, Sulkowski S, Koda M, et al. Lipid peroxidation and antioxidant status in colorectal cancer. WJG. 2005;11(3):403–406.
   PubMed Web of Science ®Google Scholar
• Veljković A, Stanojević G, Branković B, et al. Parameters of oxidative stress in colon cancer tissue. AMM. 2016;55(3):32–37.
   Google Scholar
• Ścibior D, Skrzycki M, Podsiad M, et al. Glutathione level and glutathione-dependent enzyme activities in blood serum of patients with gastrointestinal tract tumors. Clin Biochem. 2008;41(10-11):852–858.
   PubMed Web of Science ®Google Scholar
• Kocot J, Kiełczykowska M, Dąbrowski W, et al. Total antioxidant status value and superoxide dismutase activity in human colorectal cancer tissue depending on the stage of the disease: a pilot study. Adv Clin Exp Med. 2013;22(3):431–437.
   PubMed Web of Science ®Google Scholar
• Güçlü H, Doganlar ZB, Gürlü VP, et al. Effects of cisplatin-5-fluorouracil combination therapy on ­oxidative stress, DNA damage, mitochondrial apoptosis, and death receptor signalling in retinal pigment epithelium cells. Cutan Ocul Toxicol. 2018;37(3):291–304.
   PubMed Web of Science ®Google Scholar
• Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004;3(4):294–300.
   PubMedGoogle Scholar